Correction: Benefit of prompt initiation of single-inhaler fluticasone furoate, umeclidinium, and vilanterol (FF/UMEC/VI) in patients with COPD in England following an exacerbation: a retrospective cohort study

Affiliations

• ¹ Value Evidence and Outcomes, R&D Global Medical, GSK, 1250 South Collegeville Road, Collegeville, PA, USA. afisi.s.ismaila@gsk.com.
• ² Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, ON, Canada. afisi.s.ismaila@gsk.com.
• ³ Value Evidence and Outcomes, R&D Global Medical, GSK, London, UK.
• ⁴ Real-World Evidence, Adelphi Real World, Bollington, Cheshire, UK.
• ⁵ Integrated Evidence Generation (Women's Health Care), Bayer PLC, Reading, UK.
• ⁶ Global Medical, GSK, London, UK.
• ⁷ P1vital Limited, Wallingford, Oxfordshire, UK.
• ⁸ College of Medicine and Health, University of Exeter Medical School, University of Exeter, Exeter, UK.